NCT02518607View on ClinicalTrials.gov

Safety, Blood Levels and Effects of MGB-BP-3

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Healthy
Interventions
DRUG

MGB-BP-3

Treatment of CDI

OTHER

Placebo

Placebo

Sponsors
All Listed Sponsors
collaborator

Hammersmith Medicines Research

OTHER

collaborator

Innovate UK

OTHER_GOV

collaborator

Cambridge Regulatory Services

UNKNOWN

collaborator

Phases Clinical Research Limited

UNKNOWN

collaborator

Synlab Services

UNKNOWN

collaborator

Viapath

UNKNOWN

collaborator

Analytical Services International Limited

UNKNOWN

lead

MGB Biopharma Limited

INDUSTRY

NCT02518607 - Safety, Blood Levels and Effects of MGB-BP-3 | Biotech Hunter | Biotech Hunter